INS and type 1 diabetes mellitus: In the Randomized Controlled Trial Examining the Benefit of CGM Use for Adults with T1D on Insulin Injections (DIAMOND) trial (80), there was a significant HbA1c difference of -0.6% in favour of rt-CGM versus standard SMBG after 24 weeks of intervention in T1D patients on multiple daily injection (MDI).